Alkaloid AD Skopje (XMAE:ALK) EBITDA per Share: MKD1,612.90 (TTM As of Mar. 2026)


XMAE:ALK Alkaloid AD Skopje XMAE:ALK
100 GF Score
Price MKD22,500.00
GF Value MKD27,299.40
Valuation Modestly Undervalued
View Full Analysis

What is Alkaloid AD Skopje EBITDA per Share?

Alkaloid AD Skopje XMAE:ALK +0.45% 100 EBITDA per Share is MKD1,612.90 as of Mar. 2026. GuruFocus rates XMAE:ALK with a GF Score™ of 100/100 and a GF Value™ of MKD27,299.40 (Modestly Undervalued). Among 814 Drug Manufacturers companies, Alkaloid AD Skopje ranks better than 78.38% on this metric.

Alkaloid AD Skopje's EBITDA per Share for the three months ended in Mar. 2026 was MKD444.81. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MKD1,612.90.

During the past 12 months, the average EBITDA per Share Growth Rate of Alkaloid AD Skopje was 12.60% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 29.00% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 22.60% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Alkaloid AD Skopje's EBITDA per Share or its related term are showing as below:

XMAE:ALK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 1.2   Med: 9.35   Max: 29
Current: 29

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Alkaloid AD Skopje was 29.00% per year. The lowest was 1.20% per year. And the median was 9.35% per year.

XMAE:ALK's 3-Year EBITDA Growth Rate is ranked better than
78.38% of 814 companies
in the Drug Manufacturers industry
Industry Median: 8.9 vs XMAE:ALK: 29.00

Alkaloid AD Skopje's EBITDA for the three months ended in Mar. 2026 was MKD627 Mil.

During the past 12 months, the average EBITDA Growth Rate of Alkaloid AD Skopje was 12.60% per year. During the past 3 years, the average EBITDA Growth Rate was 29.10% per year. During the past 5 years, the average EBITDA Growth Rate was 22.60% per year. During the past 10 years, the average EBITDA Growth Rate was 15.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Alkaloid AD Skopje was 29.10% per year. The lowest was 1.10% per year. And the median was 9.30% per year.


Alkaloid AD Skopje  (XMAE:ALK) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Alkaloid AD Skopje EBITDA per Share Related Terms


Alkaloid AD Skopje EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Alkaloid AD Skopje's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkaloid AD Skopje EBITDA per Share Chart

Alkaloid AD Skopje Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,052.37 1,188.12 1,297.61 2,134.91 2,553.09

Alkaloid AD Skopje Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 412.14 326.39 526.91 314.78 444.81
XMAE:ALK
100GF Score
Alkaloid AD Skopje XMAE:ALK
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkaloid AD Skopje EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Alkaloid AD Skopje's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA per Share(A: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=3597.309/1.409
=2,553.09

Alkaloid AD Skopje's EBITDA per Share for the quarter that ended in Mar. 2026 is calculated as

EBITDA per Share(Q: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=626.735/1.409
=444.81

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MKD1,612.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of MKD1,612.90 mean?
Alkaloid AD Skopje (XMAE:ALK) has a EBITDA per Share of MKD1,612.90 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Alkaloid AD Skopje and its competitors. According to the industry distribution chart, Alkaloid AD Skopje ranks #176 out of 814 companies in the Drug Manufacturers industry, placing it in the top 21.6%.
Is Alkaloid AD Skopje's EBITDA per Share too high?
Alkaloid AD Skopje's current EBITDA per Share is MKD1,612.90. Based on the distribution chart, Alkaloid AD Skopje ranks #176 out of 814 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alkaloid AD Skopje has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkaloid AD Skopje's EBITDA per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alkaloid AD Skopje ranks #176 out of 814 companies for EBITDA per Share. This places Alkaloid AD Skopje in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA per Share is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Drug Manufacturers company?
The median EBITDA per Share among Drug Manufacturers companies is 8.90, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Alkaloid AD Skopje and its competitors. For the Drug Manufacturers industry, the median EBITDA per Share is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkaloid AD Skopje's current EBITDA per Share is MKD1,612.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkaloid AD Skopje stock overvalued right now?
Based on GuruFocus' analysis, Alkaloid AD Skopje (XMAE:ALK) is currently considered Modestly Undervalued. The stock's GF Value™ is MKD27,299.40, compared to a current price of MKD22,500.00 — trading 17.6% below its estimated fair value. The current EBITDA per Share is MKD1,612.90. Alkaloid AD Skopje's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Alkaloid AD Skopje (XMAE:ALK), the current EBITDA per Share is MKD1,612.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkaloid AD Skopje (XMAE:ALK) Overvalued in 2026?

Based on GuruFocus' analysis, Alkaloid AD Skopje stock appears to be undervalued. The current stock price of MKD22,500.00 is trading 17.6% below its estimated GF Value™ of MKD27,299.40. GuruFocus considers Alkaloid AD Skopje to be Modestly Undervalued.

Key valuation signals for XMAE:ALK:

  • EBITDA per Share: MKD1,612.90
  • GF Value™: MKD27,299.40 vs. price of MKD22,500.00 (17.6% below fair value)
  • GF Score™: 100/100

No single metric tells the full story. See the XMAE:ALK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alkaloid AD Skopje Business Description

Address Boulevard Aleksandar, Makedonski 12, Skopje, MKD, 1000
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.
100GF Score

Get the complete analysis for XMAE:ALK

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MKD22,500.00
Price
MKD27,299.40
GF Value